| Name | Title | Contact Details |
|---|
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first-in-class anti-cancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being evaluated in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Oncopeptides` headquarters is in Stockholm, Sweden with U.S. headquarters in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.
Verséa Health is a diversified global healthcare company engaged in scientific discovery, development and commercialization of innovative products and services intended to diagnose, manage, and treat debilitating diseases.
ValueOptions Inc., the nation's largest independent behavioral health care and wellness company, specializes in management for all behavioral health issues, and mental health and chemical dependency diagnoses.
Fagron NV is a publicly traded multinational group of companies governed by Belgian law.
Greenstone is a Peapack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.